VetCentric secures $3 million in new funding
Glen Burnie, Md. — VetCentric Inc. secured $3 million in new capital through a continued round of Series B funding. The additional funds will allow the company to develop its system of veterinarian-sponsored home medication delivery and to accelerate growth in the market, the company reports.
Sherbrooke Capital, the Asset Management Company and the Nestle Venture Capital Fund—part of Nestle S.A.—supported the investment equally.
"This investment is a great vote of confidence in the VetCentric home-delivery platform and our management team, and positions us to further build upon our recent growth," says VetCentric president and CEO Ted Root.
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
FDA approves oral drug for broad canine protection against parasites
August 6th 2025Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More